Yoon-Jae Cho, M.D.
1201 Welch Road, MSLS Bldg Rm P213
Stanford, CA 94305
Ph: 650-725-0955
Fax: 650-498-6262
Email: yjcho1@stanford.edu

Education

1990-1993 Rice University, Houston, TX. Degree: B.A., Chemistry, Anthropology
1994-2002 Oregon Health & Sciences University, Portland, OR. Degree: M.D.

Positions and Honors

Positions and Employment

2002-2003 Intern, Pediatrics, Children's Hospital of Pittsburgh / Univ of Pittsburgh Medical Center, Pittsburgh, PA
2003-2004 Resident, Pediatrics, Children's Hospital & Research Center Oakland, Oakland, CA
2004-2007 Resident, Neurology, Children's Hospital Boston, Boston, MA
2007-2008 Neuro-oncology Fellow, Children's Hospital Boston/Dana Farber Cancer Institute, Boston, MA
2008-2011 Instructor in Neurology, Harvard Medical School, Boston, MA
2008-2011 Assistant in Neurology, Children's Hospital Neurology Foundation, Inc., Boston, MA
2008-2011 Consultant in Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
2008-2011 Affiliate, Broad Institute of Harvard and MIT, Cambridge, MA
2010-2011 Associate Member, Dana-Farber/Harvard Cancer Center, Boston, MA
2011-present Assistant Professor, Departments of Neurology and Neurosurgery, Stanford University, Palo Alto, CA
2011-present Associate Member, Stanford Cancer Institute, Stanford, CA
2011-present Member, Bio-X, Stanford University, Stanford, CA
2012-present Member, Child Health Research Institute, Stanford University, Stanford, CA

Honors

1991-1993 Jones College Fellow in Chemistry, Rice University
1992 American Association of Clinical Chemistry Summer Research Fellowship
1990-1993 President's Honor Roll, Rice Univ, Fall '90, '91, '92, Spring '93
1994-2002 Oregon Medical Research Foundation Laurel MD-PhD Scholar
2002 Fred and Mary Brauti Scholarship, Oregon Health & Science University
2003 Finalist, Gold Foundation Resident Teaching Award, University of Pittsburgh School of Medicine
2007 Young Investigator Award, Pediatric Brain Tumor Foundation
2007 Young Neuroscientist Award, Childhood Neurobiological Solutions
2009, 2010 Faculty Development Award, Shore Program for Scholars in Medicine, Harvard Medical School
2011-2014 St. Baldrick's Foundation, Scholar Award
2011- Beirne Faculty Scholar in Pediatric Neuro-oncology, Stanford University School of Medicine
2012 Philip R. Dodge Young Investigator Award, Child Neurology Society

Teaching/Advising

1992-1993 Teaching Assistant, Organic Chemistry Lab, Rice University, TX
2006 Lab Instructor, Human Nervous System and Behavior, Harvard Medical School, MA
2008-2009 Undergraduate research mentor, Harvard College, Cambridge, MA
2012- Undergraduate research mentor, Stanford University, Stanford, CA (mentees: Brian Nguyen '15, Nusi Vue '14, Sabran Massoud '14, Jessie Cho '15, Brianna Balansay '15)
2012-2013 NENS205, Stanford University, Clinical Neuroscience - Brain Tumors module (course directors: Katrin Andreasson and Yan-min Yang)
2013 CBIO280, Stanford University, Cancer Biology journal club (course director: Amato Giaccia)
2013 Postdoctoral advisory committee for Jun Ni, PhD (PI: James K. Chen), Alex Brown, PhD (PI: Matthew Scott)
2013 PhD qualification committee member for Wenying Pan, Bioengineering PhD program, Stanford University: (PhD advisor: Stephen Quake)
2013 External PhD thesis committee member for Guus Bol, University Medical Center Utrecht (PhD advisor: Paul van Diest, UMC Utrecht and Venu Raman, Johns Hopkins Univ School of Medicine)

Postdoctoral trainees

2008-2012 Shyamal Dilhan Weeraratne, PhD, current position: Senior Scientist, Life Technologies
2012-2013 Sebastien Perreault, MD, current position: Assistant Professor of Neurology, Universite de Montreal and Staff

Physician, Ste Justine Hospital, Montreal, Quebec
2012- Yujie Tang, PhD
2012- Sekyung Oh, PhD
2011- Furong Yu, PhD

Professional Memberships and Committees
1994-2002 Medical Society of Metropolitan Portland
1994-2002 Oregon Medical Association
1994-2002 American Medical Association
1994-2002 American Medical Student Association
2002-2004 American Association of Pediatrics
2004- Child Neurology Society, Awards committee member (2012-)
2004- American Academy of Neurology
2010- Children's Oncology Group, CNS committee member (2010-)
2010- Society for Neuro-Oncology
2011- American Association for Cancer Research
2012- Co-Chair, Biology Committee, Pediatric Brain Tumor Consortium

Other Professional Activities:
2011- Ad hoc external grant reviewer – Cancer Research UK
2011- Ad hoc external grant reviewer – Breast Cancer Campaign
2011- Ad hoc reviewer – Cancer Research
2011- Ad hoc reviewer – Cancer Genetics
2011- Ad hoc reviewer – International Journal of Oncology
2011- Ad hoc reviewer – Journal of Neuro-oncology
2011- Ad hoc reviewer – Cancer Biology and Therapy
2011- Faculty mentor – NINDS/Assoc of Univ Prof of Neurology/Amer Neurol Assoc
2011- Advisory Board, LDE225 development – Novatis Pharmaceuticals Corp.
2012- Ad hoc reviewer – New England Journal of Medicine
2012- Ad hoc reviewer – Pediatric Blood & Cancer
2012- Ad hoc reviewer – PLoS One
2012- Grant reviewer – St. Baldrick's Foundation
2012- Medical Advisory Board – The Nicholas Conor Institute
2012- Ad hoc reviewer – European Journal of Pediatrics
2012- Ad hoc reviewer – Acta Neuropathologica
2012- Grant reviewer – The John McNicholas Foundation
2012- Applicant reviewer, Stanford University School of Medicine
2013- Grant reviewer – Italian Association for Cancer Research
2013- Ad hoc reviewer – Neuroscience
2013- Ad hoc reviewer – PNAS
2013- Ad hoc reviewer – Human Molecular Genetics

Medical Licensure:
Massachussetts(full) lic#231745, dates: 07/2007-present; *California* (full) lic#A85490, dates 05/27/2011-present; *Pennsylvania* (limited) lic#MT180515, dates: 06/2002-06/2003; Federal DEA#FC0864252 06/09/2008-present

Board Certification:
American Board of Psychiatry and Neurology (ABPN), with special qualifications in Child Neurology, Part I (written) passed 1/2008, Part II (oral) passed 4/30/2009.

Publications/presentations (*in chronological order; *corr author; #contr equally*)
Peer Reviewed:
1. Wu AH, Liu N, **Cho YJ**, Johnson KG, Wong SS. Extraction and simultaneous elution and derivatization of 11-nor-9-carboxy-delta 9-tetrahydrocannabinol using Toxi-Lab SPEC prior to GC/MS analysis of urine. *J Anal Toxicol* 1993 Jul-Aug;17(4):215-7.

2. **Cho YJ**, Chema D, Moskow JJ, Cho M, Schroeder WT, Overbeek P, Buchberg AM, Duvic M. Epidermal surface antigen (MS17S1) is highly conserved between mouse and human. *Genomics* 1995 May 20;27(2):251-8.

3. Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, **Cho J**, Deng C, Horton WA, Fu XY. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. *Nature* 1997 Mar 20;386(6622):288-92.

4. Lunstrum GP, Keene DR, Weksler NB, **Cho YJ**, Cornwall M, Horton WA. Chondrocyte differentiation in a rat mesenchymal cell line. *J Histochem Cytochem* 1999 Jan;47(1):1-6.

5. Grant TD, **Cho J**, Ariail KS, Weksler NB, Smith RW, Horton WA. Col2-GFP reporter marks chondrocyte lineage and chondrogenesis during mouse skeletal development. *Dev Dyn* 2000 Jun;218(2):394-400.

6. **Cho J**, Guo C, Torello M, Lunstrum GP, Iwata T, Deng C, Horton WA. Defective lysosomal targeting of activated FGFR3 in achondroplasia. *Proc Natl Acad Sci USA* 2004 Jan 13;101(2):609-14. PMC327195

7. Guo C, Degnin CR, Laederich MB, Lunstrum GP, Holden P, Bihlmaier J, Krakow D, **Cho YJ**, Horton WA. Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia. *Cell Signal.* 2008 Aug;20(8):1471-7. Epub 2008 Apr 10. PMC2675614

8. McKenna ES, Sansam CG, **Cho YJ**, Greulich H, Evans JA, Thom CS, Curran T, Biegel JA, Pomeroy SL, Roberts CWM. Loss of the epigenetic tumor suppressor Snf5 leads to cancer without genomic instability. *Mol Cell Biol*. 2008 Oct;28(20):6223-33. Epub 2008 Aug 18. PMC2577431

9. Lipton J, Megerian JT, Kothare SV, **Cho YJ**, Shanahan T, Chart H, Adler-Golden L, Ferber R, Cohen LE, Czeisler CA, Pomeroy SL. Melatonin Deficiency and Disrupted Circadian Rhythms in Pediatric Survivors of Craniopharyngioma. *Neurology*. 2009 Jul 28;73(4):323-5. PMC2715212

10. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, McHenry KT, Pinchback R, Ligon AH, **Cho YJ** . . . Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alterations across multiple human cancer types. *Nature*. 2010 Feb 18;463(7283):899-905. PMC2826709

11. Teider N, Scott DK, Neiss A, Weeraratne SD, Amani VA, Wang Y, Marquez VE, **Cho YJ**, Pomeroy SL. Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. *Neuro-oncology*. 2010 Dec;12(12):1244-56. Epub 2010 Sep 16. PMC3018940

12. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, **Cho YJ**, Koellhoffer EC, Pomeroy SL, Orkin SH, Roberts CWM. Epigenetic antagonism between Polycomb and SWI/SNF complexes during oncogenic transformation. *Cancer Cell.* 2010 Oct 19;18(4):316-28. PMC2957473

13. **Cho YJ**, Tsherniak A, Tamayo P, Santagata S, Greulich H, Berhoukim R, . . . Meyerson M, Mesirov JM, Pomeroy SL. Integrative genomic analysis of medulloblasotma identifies a molecular subgroup that drives poor clinical outcome. *J Clin Onc*. 2011 Apr 10;29(11):1424-30. Epub 2010 Nov 22. PMC3082983

14. Jagani Z, Mora-Blanco EL, Sansam CG, McKenna ES, Wilson B, Chen D, Klekota J, Tamayo P, Nguyen PTL, Tolstorukov M, Park PJ, **Cho YJ**, Hsiao K, Buonamici S, Pomeroy SL, Mesirov JP, Ruffner H, Bouwmeester T, Luchansky S, Murtie J, Kelleher J, Warmuth M, Sellers WR, Roberts CWM, Dorsch M. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. *Nature Medicine*. 2010 Dec;16(12):1429-33. Epub 2010 Nov 14.

15. Weeraratne SD, Amani VA, Neiss A, Scott, DK, Teider N, Pomeroy SL, **Cho YJ***. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. *Neuro-Oncology*. 2011 Feb;13(2):165-75. Epub 2010 Dec 22. PMC3064629

16. Balaj L, Lessard R, Dai L, **Cho YJ**, Pomeroy SL, Boeke JD, Breakefield XO, Skog J. Tumor microvesicles contain retrotransposon elements and amplified oncogene sequences. *Nature Comm*. 2011 Feb;2:180. PMC3040683

17. Tamayo P#, **Cho YJ#**, Tsherniak A, Greulish H, Ambrogio L, Schoutten-van Meeteren, Zhou T, Buxton A, Kool M, Meyerson M, Pomeroy SL, Mesirov JM. Predicting relapse in medulloblasotma patients by integrating evidence from clinical and genomic features. *J Clin Onc*. 2011 Apr 10;29(11):1415-23. Epub 2011 Feb 28. PMC3082982

18. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Roberts SS, Massimi L, van Meter T, Weiss WA, Gupta N, Grajkowska W, Lach B, **Cho YJ**, von Deimling A, Kulozik AE,

Witt O, Bader G, Guha A, Rutka JT, Lichter P, Korshunov A, Taylor MD# Pfister SM# Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. *Cancer Cell*. 2011; 20 (2): 143-57.

19. Priller M, Poschl J, Abrao L, von Bueren AO, **Cho YJ**, Rutkowski S, Kretzschmar HA, Schuller U. Expression of FoxM1 is required for the proliferation of medulloblastoma cells and indicates worse survival of patients. *Clin Cancer Res*. 2011 Nov 1;17(21):6791-801. Epub 2011 Sep 14.

20. Northcott PA, Shih DJ, Remke M, **Cho YJ**, Kool M, Hawkins C, Eberhart C, Dubuc A, Toumy G, Cardentey Y, Bouffet E, Pomeroy SL, Rutka JT, Korshunov A, Pfister SM, Taylor MD. Rapid, reliable and reproducible molecular sub-grouping of clinical medulloblastoma samples. *Acta Neuropathol*. 2012 Apr;123(4):615-26. Epub 2011 Nov 6. PMC3306784

21. Korshunov K, Remke M, Kool M, Hielscher T, Northcott PA, Williamson D, Witt H, Jones DTW, Ryzhova M, **Cho YJ,** Wittmann A, Benner A, Westermann F, von Deimling A, Scheurlen V, Kulozik AE, Clifford S, Collins VP, Taylor MD, Lichter P, and Pfister SM. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. *Acta Neuropathol*. 2012 Apr;123(4):515-27. Epub 2011 Dec 9.

22. Bai AHC, Milde T, Remke M, Rolli CG, Hielscher T, **Cho YJ**, Kool M, Northcott PA, Jugol M, Bahzin AV, Eichmuller SB, Kulozik AE, Pscherer A, Benner A, Taylor MD, Pomeroy SL, Kemkemer R, Witt O, Korshunov A, Lichter P, Pfister SM. MicroRNA-182 promotes metastatic dissemination of non-sonic hedgehog-medulloblastoma. *Acta Neuropathol*. 2012 Apr;123(4):529-38. Epub 2011 Dec 2.

23. Taylor MD, Northcott PA, Korshunov A, Remke M, **ChoYJ**, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison D, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular Subgroups of Medullobalstoma: The Current Consensus. *Acta Neuropathol*. 2012 Apr;123(4):465-72. Epub 2011 Dec 2. PMC3306779

24. Pei Y, Moore C, Read TA, Sun LL, Miller CR, McLendon RE, Buckley AF, Eroshkin A, Tewari A, Febbo PG, **Cho YJ**, Pfister SM, Korshunov A, Northcott PA, Taylor MD, Wechsler-Reya RJ. Dysregulation of c-MYC and p53 transforms cerebellar stem cells into large cell anaplastic medulloblastoma. *Cancer Cell*. 2012; 21 *(2): 155-67*. PMC3285431

25. Wu X, Northcott PA, Dubuc A, Dupuy A, Garzia L, Eberhart C, Witt H, Van Meter T, Zagzag D, Croul S, Scheetz T, Pfister S, Korshunov A, Bouffet E, Scherer S, **Cho YJ**, Akagi K, McDonald T, Koster J, Sarver A, Collins VP, Weiss W, Largaespada D, Collier L, Taylor MD. Genetic divergence of medulloblastoma due to clonal selection. *Nature*. 2012 Feb 15;482(7386):529-33. PMC3288636

26. Kool M, Korshunov A, Remke M, Jones DTW, Schlanstein M, Northcott PA, **Cho YJ**, Koster J, Schouten-van Meeteren A, van Vuurden, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Backlund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM. Molecular subgroups of medulloblasotma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblasotmas. *Acta Neuropathol*. 2012 Apr;123(4):473-84. Epub 2012 Feb 23. PMC3306778

27. Tran PT, Shroff E, Burns T, Thijagarajan S, Das S, Zabuawala T, Chen J, **Cho YJ**, Luong R, Tamayo P, Salih T, Aziz K, Adam S, Vicent S, Nielsen C, Withofs N, Sweet-Cordero A, Gambhir S, Rudin C, Felsher DW. Twist1 accelerates and maintains mutant Kras-induced lung tumorigenesis. *PLoS Genetics*. 2012 May;8(5):e1002650. Epub 2012 May 24. PMC3360067

28. Weeraratne SD, Amani VA, Teider N, Pierre-Francois J, Kye MJ, Sengupta S, Archer T, Remke M, Bai AHC, Warren P, Pfister SM, Steen JAJ, Pomeroy SL, **Cho YJ*.** Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. *Acta Neuropathol*. 2012 Apr;123(4):539-52. Epub 2012 Mar 10. PMCID in process

29. McKenna ES, Tamayo P, **Cho YJ**, Tillman EJ, Mora-Blanco EL, Sansam CG, Koellhoffer EC, Pomeroy SL, Roberts CWM. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. *Cell Cycle.* 2012 May 15;11(10):1956-65. Epub 2012 May 15. PMC3359122

30. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, … Roberts TM, Meyerson M, Pomeroy SL, **Cho YJ*.** Medulloblasotma exome sequencing uncovers subtype-specific somatic mutations. *Nature*. 2012 Aug 2;488(7409):106-10. 2012 Aug 2;488(7409):106-10. Epub 2012 Jul 22.

31. Jones DTW, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, **Cho YJ**, Pugh TJ, … Taylor MD, Meyerson M, Pomeroy SL,

Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P. Dissecting the genomic complexity underlying medulloblastoma. *Nature*. 2012 Aug 2;488(7409):100-5. Epub 2012 Jul 25.

32. Northcott PA, Shih DJH, Peacock J, Garzia L, Morrissy S, … Sorensen PHB, Meyerson M, Pomeroy SL, **Cho YJ**, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJM, Korbel JO, Pfister SM, Marra MA, Taylor MD. Subgroup-specific structural variation across 1,000 medulloblasotma genomes. *Nature*. 2012 Aug 2;488(7409):49-56. Epub 2012 Jul 25.

33. Burns TF, Dobromilskaya I, Murphy SC, Gajula RP, Thiyagarajan S, Chatley SN, Aziz K, **Cho YJ**, Tran PT, Rudin CM. Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene Driven Non-Small Cell Lung Cancer. *Mol Cancer Res*. 2013 Apr;11(4):329-38.

34. Mora-Blanco EL, Mishina Y, Tillman EJ, **Cho YJ**, Thom CS, Pomeroy SL, Shao W, CWM Roberts. Activation of b-catenin/TCF targets following loss of the tumor suppressor SNF5. *Oncogene*. 2013 Feb 25.

35. Yuan L, Zhang H, Liu J, Rubin JB, **Cho YJ**, Shu HK, Schniederjan M, Macdonald TJ. Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration. *Mol Cancer*. 2013 Mar 5;12:18.

36. Jones DTW, Hutter B, Jäger N, Korshunov A, Kool M,… **Cho YJ**, Pomeroy SL, von Deimling A, Witt O, Taylor MD, Korbel JO, Wolf S, Yaspo ML, Hasselblatt M, Karajannis MA, Eberhart CG, Scheurlen W, Ligon KL, Kieran MW, Brors B, Felsberg J, Reifenberger G, Collins VP, Jabado N, Eils R, Lichter P and Pfister SM. Recurrent *FGFR1* hotspot mutations represent a novel therapeutic target in childhood astrocytoma. *Nature Genetics.* 2013 Jun 30 [Epub ahead of print].

37. Ramkissoon LA, Horowitz PM, Craig JM, Ramkissoon SH, … **Cho YJ**, … Getz G, Chan JA, Santagata S, Hahn WC, Stiles CD, Ligon AH, Kieran MW, Beroukhim R, Ligon KL. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent, oncogenic MYBL1-truncating rearrangements. *PNAS.* 2013 May 14;110(20):8188-93.

38. Dykhuizen EC, Hargreaves DC, Miller E, Sun A, Dave S, Korshunov A, Pfister SM, **Cho YJ**, Zhao K, Crabtree GR. mSWI/SNF (BAF) Complexes Facilitate Decatentation of DNA by Topoisomerase IIa. *Nature.* 2013 May 30;497(7451):624-7.

39. Ullrich NJ, Kieran MW, Miller DT, Gordon LB, **Cho YJ**, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. *Neurology.* 2013 Jun 28 [Epub ahead of print].

40. Zhukova N, Ramaswamy V, Remke M, Shih DJH, Martin DC, … **Cho YJ**, Pietsch T, … Clifford S, Pfister SM, Taylor MD, Tabori U. Subgroup specific prognostic implications of TP53 mutation in medulloblastoma. *J Clin Onc*. 2013 Jul 8 [Epub ahead of print].

41. Bender S#, Tang Y#, Lindroth AM#, Hovestadt V, Sturm D, Kool M, Jones DTW,… von Deimling A, Jabado N, Puget S, Grill J, Helin K, Korshunov A, Lichter P, Monje M, Plass C*, **Cho YJ***, Pfister SM***.** Histone H3.3 K27M mutations in pediatric high grade gliomas lead to functional loss of PRC2 activity. *Cancer Cell, In press.*

42. Hackett C, Quigley DA, Fan QW, Cheng C, Song YK, Pawlikowska L, Chen J, Bao Y, Goldenberg DD, Nguyen K, **Cho YJ**, Rallapalli S, Cook JM, Kozlov S, Mao JH, Van Dyke T, Kwok PY, Khan J, Balmain A, Weiss WA. eQTL and receptor pharmacology implicate GABA signaling in neuroblastoma. *In review*.

43. Sengupta S, Weeraratne SD Sun H, Rallapalli S, Phallen J, Teider N, Pierre-Francois J, Amani V, Tang Y, Nguyen B, Yu F, Schubert S, Mathios D, Lechpammer M, Kosaras B, Tran P, Cook JM, Lim M, Pomeroy SL, Jensen F, **Cho YJ***. Chemical synthetic lethality via a5-GABAA receptor activation in *MYC*-amplified medulloblastomas. *In review*.

44. Shou Y, Robinson D, Amakye D, Rose K, **Cho YJ**, Ligon KL, Sharp T, Haider A, Bandaru R, Ando Y, Geoerger B, Doz F, Ashley D, Hargrave D, Casanova M, Tawbi H, Rodon J, Thomas A, Mita A, MacDonald T, Kieran MW. A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma. *In review*.

45. Kool M, Jones DTW, Jäger N, Northcott PA, Pugh TJ, Hovestadt V, Piro R, Esparza LA, Markant S, Remke M, Milde T, Bourdeaut F, Rizhova M, Sturm D,… Kieran MW, **Cho YJ**, Pomeroy SL, Witt O, Brors B, Taylor MD, Schüller U, Korshunov A, Eils R, Wechsler-Reya R, Lichter P, Pfister SM. Genome sequencing of SHH medulloblastoma predicts age-dependent response to smoothened-inhibition. *In revision.*

46. Mack SC, Witt H, Jager N, Zuyderduyn S, Jones DTW, Nethery-Brokx K, Stark S, Hutter S, Garzia L, Stütz A, Zichner T, Zayne K, Wang X, Barszczyk M, Wani KM, Pugh TJ, Shih D, Sill M, Seker-Cin H, Bender S, Johann P, Hovestadt V, Tzaridis T, Kongkham PN, Dubuc AM, Ramaswamy V, Peacock J, Remke M, Koster J, Northcott PA, Bertrand KC, Milde T, Zuccaro J, Lau L, Faria CC, Castelo-Branco P, Roberts SS, Fults D, Massimi L, **Cho YJ**, Van Meter T, Grajkowska W, Lach B, Kulozik AE, von Deimling A, Witt O, Scherer SW, Fan X, Kool M, Pomeroy S, Bouffet E, Gupta N, Weiss WA, Tabori U, Hawkins C, Rutka JT, Korbel J, Lichter P, Bader GD, Aldape KD, Dirks PB, Pfister SM, Korshunov A, Taylor MD. Effective epigenetic therapy for CIMP+ve ependymoma. *In revision*.

47. Shih DJH, Northcott PA, Remke M, Korshunov A, Ramaswamy V, Kool M, … **Cho YJ**, Tabori U, Olson JM, Gajjar A, Packer RJ, Rutkowski S, Pomeroy SL, French PJ, Kloosterhof NK, Kros JM, Van Meir EG, Clifford SC, Delattre O, Doz FF, Reynaud SS, Hawkins CE, Malkin DE, Grajkowska WA, Perek-Polnik M, Bouffet E, Rutka JT, Pfister SM, Taylor MD. Cytogenetic prognostication within medulloblastoma subgroups. *In review*.

48. Bandopadhayay M, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Masoud S, Yu F, Vue N, Schumacher SE, Gibson WJ, Paolella BR, Mitra S, Cheshire S, Qi J, Liu KW, Wechsler-Reya R, Weiss WA, Swartling F, Kieran MW, Bradner JE, Beroukhim R, **ChoYJ***. BET-bromodomain inhibition of MYC-amplified medulloblastomas. *In revision*.

49. Rack P, Ni J, Kool M, Hovestadt V, Jones DTW, Pfister SM, **ChoYJ**, Chen JK. Arhgap36-dependent activation of Gli transcription factor function. *In review*.

50. Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, **Cho YJ**, Shih DJH, Luu B, Dubuc AM,… Packer RJ, Pfister SM, Korshunov A, Taylor MD. Recurrence patterns differ between medulloblastoma subgroups. *In review*.

51. Tang Y, Schubert S, Bandopadhayhay P, … Oro T, Bradner JE, **ChoYJ***. Epigenetic regulation of Hedgehog transcriptional output by BRD4 reveals a therapeutic strategy to overcome acquired and a priori resistance to Smoothened antagonists. *In review.*

52. Peterson W, Liu J, Yuan L, Zhan H, Schneiderjan M, **ChoYJ**, MacDonald TJ. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. *In review.*

53. Yu F, Masoud S, Chen C, Gholamin S, Mitra S, Tolliday N, Cheshire S, Mochly-Rosen D, Schreiber S, **Cho YJ***. High-throughput chemical biology screen identifies ALDH3A1 as a therapeutic target in Group 3/*MYC*-amplified medulloblastoma. *In preparation.*

54. Perreault S, Ramaswamy V, Achrol A, Shih DJH, Remke M, Luu B, Schubert S, Pouissant T, Partap S, Fisher PG, Vogel H, Taylor MD, Yeom K, **Cho YJ***. Identification of MRI surrogates for molecular subtypes of medulloblastoma. *In preparation.*

Book Chapters:

Cho YJ, Pomeroy SL. "Brain and Spinal Cord Tumors", in Current Management in Child Neurology, 4th Edition, Edited by Bernard L. Maria. People's Medical Publishing House 2008.

Cho YJ, Pomeroy SL. "Medulloblastoma", in Molecularly Targeted Therapy for Childhood Cancer, Edited by Robert Arceci and Peter J Houghton. Springer 2009.

Kieran MW, Kalluri R, **Cho YJ**. "The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward" in *CSH Perspectives*, Eds: Michael Klagsbrun and Patricia D'Amore. CSH Press 2011.

Tang Y and **Cho YJ**. "Regulation of Cell Survival, Proliferation, and Migration in Medulloblastoma: Role of microRNAs" in Tumors of the Central Nervous System. *In preparation*.

Invited Publications:

Cho J, Grant TD, Lunstrum GP, Horton WA. Col2-GFP reporter mouse-a new tool to study skeletal development. *Am J Med Genet* 2001 Winter;106(4):251-3.

Rasar MA, **Cho J**, Lunstrum GP, Horton WA. Fibroblast growth factor (FGFR) mutations in achondroplasia and related skeletal dysplasias. *Proc First Internatl Conf Growth Plate* 2001.

Cho YJ and Pomeroy SL. Molecular fingerprints of medulloblastoma and their application to clinical practice. *Future Oncol* 2011 Mar;7(3):327-9.

Oh S and **ChoYJ**. Molecular mechanisms that regulate medulloblastoma. WIREs Systems Biology and Medicine. *In preparation*.

Invited Presentations:

Plenary session presentation, Society for Investigative Dermatology, Baltimore, MD, 05/1994, "Epidermal surface antigen cDNA is highly conserved".

Stem Cell Symposium, Children's Hospital Boston, 12/21/2007, "Developmental Pathways In Medulloblastoma Pathogenesis".

Neurology Grand Rounds, Oregon Health & Science University, 09/09/2009, "An Integrative Genomic Analysis of Medulloblastoma".

Plenary session, 14th International Symposium on Pediatric Neuro-oncology, Vienna, Austria, 06/21/2010, "Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome".

Neurology Grand Rounds, Harvard Medical School, 9/1/2010, "Risk-stratification and targeted therapy development in medulloblastoma using an integrative genomics approach".

Children's Oncology Group, CNS committee, Medulloblastoma breakout session, Dallas, TX, 9/23/2010, "Integrative genomic analysis identifies molecular subtype that drive poor clinical outcome in medulloblastoma".

Molecular Radiation Sciences Seminar Series, Department of Radiation Oncology, Johns Hopkins Medical Center, 10/27/2010, "Medulloblastoma risk stratification using an integrative genomics approach".

Division of Hematology/Oncology Seminar Series, Children's Hospital Boston/Dana-Farber Cancer Institute, 2/17/2010, "Molecular classification and risk-stratification in medulloblastoma using an integrative genomics approach".

Sanford-Burnham Institute, San Diego, CA, 03/03/2011, "Molecular classification and risk-stratification in medulloblastoma using an integrative genomics approach".

Minisymposium presentation, Amer Assoc for Cancer Research, Orlando, FL, 04/05/2011, "Molecular classification and risk-stratification in medulloblastoma using an integrative genomics approach".

Multidisciplinary Neuro-Oncology Conference, Dana-Farber/Brigham and Women's Hospital, 4/15/2011, "Molecular classification and risk-stratification in medulloblastoma".

Society for Neuro-oncology, Pediatric Neuro-oncology Basic and Translational Research meeting, New Orleans, 5/19-20/2011, "Next-generation high throughput sequencing reveals an FBXW7 mutation in a SHH pathway medulloblastoma".

Society for Neuro-oncology, Pediatric Neuro-oncology Basic and Translational Research meeting, New Orleans, 5/19-20/2011, "The miR-183~96~182 cluster inhibits cellular senescence and promotes survival in 'high-risk' medulloblastoma".

Neurology Grand Rounds, Stanford University School of Medicine, 12/2/2011, "Top-down and bottom-up approaches to understanding and treating medulloblastoma".

Invited speaker, Helen Diller Family Comprehensive Cancer Center "Pediatric Malignancies" Symposium, UCSF, 4/26/2012, "Top-down and bottom-up approaches to understanding and treating medulloblastoma".

19th International Brain Tumor Research and Therapy Conference, Niagara Falls, Canada, 6/24/2012, "Leveraging a5/GABA-A receptor expression in medulloblastoma as a novel therapeutic approach".

Plenary session, 15th International Symposium on Pediatric Neuro-oncology, Toronto, Canada, 06/24/2010, "Medulloblastoma exome sequencing uncovers subtype-specific mutations within a broad landscape of genetic heterogeneity".

Breakfast Symposium, 15th International Symposium on Pediatric Neuro-oncology, Toronto, Canada, 06/25/2010, "Patient selection strategies in the treatment of medulloblastoma".

Neurosurgery Grand Rounds, Stanford University School of Medicine, 08/25/2012, "Medulloblastomics".

Pediatrics Grand Rounds, Lucile Packard Children's Hospital/Stanford University School of Medicine, 09/28/2012, "Medulloblastoma: From bedside to bench and back again".

The Global Symposium on Childhood Brain Tumors, Bunker Bay, Western Australia, 02/13/2013, "Lead generation and characterization in MYC-driven medulloblastoma".

Research Seminar and parent/public forum, Telethon Institute for Child Health Research, Perth, Australia, 02/14/2013, "Medulloblastoma: From bedside to bench and back".

Division of Pediatric Hematology-Oncology, Research Seminar Series, Texas Children's Hospital, Houston, TX, 02/28/2013, "Medulloblastoma: A journey from bedside to bench and back".

Brain Tumor Seminar Series, Memorial Sloan-Kettering Cancer Center, New York, NY, 9/22/2013, "Identifying and targeting genetic and epigenetic vulnerabilities in medulloblastoma".

Department of Pathology, University Medical Center, Utrecht, NL, 12/4/2013, "TBD".

Medulloblastoma in the Mountains, St. Moritz, Switzerland, 1/13-16/2014, "TBD".

Brain Tumor session, SIOP Asia Congress, Seoul, Korea, 4/19/2014, "TBD".

Research Support

Current and Pending

1U01CA176287-01 Weiss, Balmain, Cho (co-PIs) 05/01/2013-03/31/2017
Genetic network analysis of cancer targets
Agency: National Cancer Institute / Cancer Target Discovery and Development Network

Large-Scale Applied Research Project Taylor, Malkin (co-PIs) 07/01/2011-06/30/2014
Stratifying and Targeting Pediatric Medulloblastoma Through Genomics
Agency: Genome Canada

Scholar Award Cho (PI) 09/01/2011-08/31/2014
Functional annotation of the medulloblastoma genome
Agency: St. Baldrick's Foundation

NIH Pediatric Loan Repayment Program Cho (PI) 07/01/2008-06/31/2013 (renewal pending)
Functional annotation of the medulloblastoma genome
Agency: National Institute of Neurological Disorders and Stroke

Scholar Award Tran (PI) 7/01/2012-06/30/2016
Twist1 structure-function studies of Kras-induced senescence inhibition
Agency: American Cancer Society

Young Investigator Award Cho (PI) 10/01/2012-09/30/2014
Genetic and pharmacological manipulation of the medulloblastoma genome
Agency: Child Neurology Society

1R01CA166348-01A1 Tran (PI) 05/01/2013-04/30/2018
Structure-function studies of Twist1-induced radioresistance in lung cancer
Agency: National Cancer Institute

Completed

National Organization for Rare Disorders Sahin (PI) 08/01/2007-07/31/2009
Genome-wide Linkage analysis of Moyamoya syndrome Using High density single Nucleotide Polymorphism Genotyping Arrays, Agency: National Organization for Rare Disorders

T32 Post-doctoral Training Grant Greenberg (PI) 07/01/2007-06/30/2008
Developmental Neurology Training Grant Award
Agency: National Institute of Neurological Disorders and Stroke

Research Grant Cho (PI) 08/01/2010-07/31/2011
Targeting FGF receptor signaling in atypical teratoid/rhabdoid tumors
Agency: Bear Necessities Pediatric Cancer Research Foundation

1RC2HL101631-01 Kieran (PI) 09/30/2009-08/31/2011
Phase II trial of lonafarnib, pravastatin and zolendric acid in progeria.
Agency: National Heart, Lung and Blood Institute

Faculty Development Award Cho (PI) 07/01/2009-06/30/2011
Eleanor and Miles Shore Fellowship Program for Scholars in Medicine
Agency: Harvard Medical School

Faculty Grant for Undergraduate Research Cho (PI) 09/01/2011-08/31/2012
Agency: Stanford University, Vice Provost for Undergraduate Education

Center Initiated Project Meyerson (PI) 12/01/2010-11/31/2012
Next-generation sequencing of medulloblastoma
Agency: National Human Genome Research Institute